

October 31, 2018



# CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018

MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it will release its third quarter 2018 financial results after the market closes on Wednesday, November 14, 2018, followed by a conference call on which the company's management will discuss the results and provide a company update.

## Details for the Conference Call:

Date: November 14, 2018  
Time: 2:00 p.m. (Pacific Time)

## Conference Audio

- Dial-in U.S. and Canada: (888) 394-8218
- Dial-in International: (323) 701-0225
- Conference ID No.: 1659879

We kindly request that you call into the conference audio approximately 10 minutes before the start time so that we can begin promptly.

An audio replay of the call will be available beginning at 5:00 p.m. Pacific Time on November 14, 2018, through 9:00 p.m. Pacific Time on December 5, 2018. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID No. 1659879. The audio replay will also be available at [www.cohbar.com](http://www.cohbar.com) from November 14, through December 5, 2018.

## About CohBar

CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs. For additional company

information, please visit [www.cohbar.com](http://www.cohbar.com).

**Investor and Media Contacts:**

Jeff Biunno, CFO

CohBar, Inc.

(650) 446-7888, Option 3

[jeff.biunno@cohbar.com](mailto:jeff.biunno@cohbar.com)

Joyce Allaire

LifeSci Advisors, LLC

[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)



Source: CohBar, Inc.